Canaccord Adams Initiates Voverage on AVEO Pharmaceuticals (AVEO) with a Buy; Best-in-Class Cancer Drug Moves Forward
Tweet Send to a Friend
Canaccord Adams initiates coverage on AVEO Pharmaceuticals (Nasdaq: AVEO) with a Buy. PT $14.
Canaccord analyst says, "Tivozanib could be ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Canaccord analyst says, "Tivozanib could be ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
